Comparison of Injectable Platelet-rich Fibrin and Semilunar Flap with Tuberosity Graft for Gingival Black Triangles: A Randomized Clinical Trial.

AIM: To evaluate and compare the clinical efficacy of injectable platelet-rich fibrin (i-PRF) and semilunar coronally positioned flap (SCPF) with tuberosity connective tissue graft (T-CTG) in the management of gingival black triangles (GBTs).

MATERIALS AND

METHODS

Twenty patients who presented with class I and class II gingival black triangles (GBTs) were split into two groups for a randomized clinical trial: SCPF with TCTG and i-PRF. At baseline, 3, and 6 months after treatment, clinical measures such as papillary height, black triangle decrease, and periodontal pocket depth were measured.

RESULTS

Both groups demonstrated significant improvements in clinical parameters and patient satisfaction. The i-PRF group exhibited faster healing and greater patient comfort, while the SCPF with TCTG group achieved superior aesthetic outcomes with greater black triangle closure. However, the SCPF group experienced more postoperative discomfort and required longer healing times.

CONCLUSION

The i-PRF and SCPF with TCTG are effective in managing GBTs, with each having distinct advantages. i-PRF offers a minimally invasive option with enhanced healing, whereas SCPF with TCTG provides superior aesthetic results. Clinical goals and patient requirements should guide the selection of the best approach.

CLINICAL SIGNIFICANCE: The study highlights two effective approaches for managing GBTs, catering to diverse clinical and patient needs. i-PRF offers a minimally invasive method with faster healing and enhanced comfort, while SCPF with graft-CTG (SCPF with T-CTG) ensures superior aesthetic outcomes, aiding personalized periodontal therapy decisions. How to cite this article: Punse S, Dhadse P, Salian S, et al. Comparison of Injectable Platelet-rich Fibrin and Semilunar Flap with Tuberosity Graft for Gingival Black Triangles: A Randomized Clinical Trial. J Contemp Dent Pract 2025;26(4):418-425.